SCHEMBL6992014

SCHEMBL6992014

O=C1Nc2ccc(Cl)cc2Nc2sc3ccccc3c21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.51
KDM4E B2RXH2 1/20 0.47
POLB P06746 2/20 0.45
MAPT P10636 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
MEN1 O00255 1/20 0.45
DUSP3 P51452 1/20 0.45
BLM P54132 1/20 0.45
PTPN5 P54829 1/20 0.45
KMT2A Q03164 1/20 0.45
PTPN11 Q06124 1/20 0.45
MCL1 Q07820 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CES1 P23141 3/20 0.40
TGM2 P21980 1/20 0.40
LRRK2 Q5S007 2/20 0.39
CDK4 P11802 2/20 0.37
CCND1 P24385 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6997683 1.00 CHEK1 (0.51) CHEK1KDM4EPOLBMAPTTDP1
SCHEMBL6994939 0.89 MAPT (0.43) CHEK1KDM4EPOLBMAPTTDP1
SCHEMBL6995596 0.87 MAPT (0.49) CHEK1KDM4EPOLBMAPTTDP1
SCHEMBL6992903 0.86 POLB (0.45) CHEK1KDM4EPOLBMAPTTDP1
SCHEMBL6990173 0.86 POLB (0.45) CHEK1KDM4EPOLBMAPTTDP1
SCHEMBL6994826 0.86 CHEK1 (0.47) CHEK1KDM4EPOLBMAPTTDP1
SCHEMBL6996333 0.85 MAPT (0.44) CHEK1KDM4EPOLBMAPTTDP1
SCHEMBL6994996 0.85 CSNK1G1 (0.50) CHEK1POLBMAPTTDP1MEN1
SCHEMBL6993425 0.85 MAPT (0.44) CHEK1KDM4EPOLBMAPTTDP1
SCHEMBL6998420 0.85 CSNK1G1 (0.50) CHEK1POLBMAPTTDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP claimed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP claimed
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT CHEK1 3269/4885KDM4E 3066/4885POLB 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.